Cyclerion Therapeutics held shareholder meeting, quorum met

Cyclerion Therapeutics held its annual shareholder meeting on Aug. 26, 2026, with investors voting on merger-related proposals.

• Share issuance tied to the merger won shareholder backing, clearing a change-of-control step linked to the transaction.
• Charter amendment to raise authorized common shares to 700 million from 400 million was adopted.

• Reverse stock split was authorized; the board later set a 1-for-7 ratio, pending effectiveness upon filing.
• Redomestication to the Cayman Islands failed; the combined company is expected to trade as Korsana Biosciences under KRSA on Sept. 9, 2026.